- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.05. | Cytospire hauls in $83M for a new type of T cell engager | ||
| 04.05. | Celcuity strengthens case for ASCO-spotlighted breast cancer drug | ||
| 04.05. | With $97M, Latus pursues a different kind of Huntington's gene therapy | ||
| 04.05. | UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases | ||
| 04.05. | What is your AI drug repurposing strategy missing? | ||
| 01.05. | Arvinas' 'Protac' breast cancer drug cleared by FDA | ||
| 01.05. | Summit's 'self-inflicted' stumble; Esperion's take-private deal | ||
| 01.05. | Moderna sees revenue bump from international COVID vaccine sales | ||
| 01.05. | Bristol Myers' legacy lift, Biogen's blue skies and Regeneron's murky outlook | ||
| 30.04. | Merck still sees 'compelling' outlook for Terns leukemia drug | ||
| 30.04. | UniQure, in 'symbolic' win, to seek UK approval of Huntington's gene therapy | ||
| 30.04. | Lilly posts another 'blowout quarter' as focus turns to Foundayo launch | ||
| 29.04. | Teva nabs experimental Tourette drug in $700M Emalex buyout | ||
| 29.04. | Chiesi to buy KalVista in $1.9B deal for rare disease drug | ||
| 29.04. | FDA tests out 'real-time' clinical trials; AbbVie closes in on a KRAS biotech | ||
| 28.04. | Pfizer deals extend patent life for a top-selling rare disease drug | ||
| 28.04. | Boehringer dual-acting obesity shot hits mark in Phase 3 trial | ||
| 28.04. | FDA claims Amgen drug data were 'manipulated'; Erasca slides despite 'home run' results | ||
| 28.04. | Coultreon banks $125M to support testing of former Galapagos immune drug | ||
| 28.04. | Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead. | ||
| 27.04. | Oruka surges as long-acting psoriasis drug shows early promise | ||
| 27.04. | Veradermics soars on positive data for baldness treatment | ||
| 27.04. | Lilly to buy startup Ajax in bid for a better JAK drug | ||
| 27.04. | Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder | ||
| 24.04. | Sanofi MS drug rejected in US gets an endorsement in Europe |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.